Atlas Trials

Fruquintinib Plus Camrelizumab and Capecitabine as Salvage Therapy After Progression on FOLFOXIRI-based First-line Treatment in Patients With Unresectable/Metastatic Colorectal Cancer

Clinical trial NCT06148402 · UNKNOWN

Trial details

NCT number
NCT06148402
Sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Unresectable/Metastatic Colorectal Cancer
Start date
2023-11-08
Primary completion
2025-12-31
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.